Optimising the treatment pathway for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
This symposium was part of the British Society of Haematology (BSH) 2021 congress, and was sponsored by Roche Products Ltd. It took place on Sunday 25th April 2021.
- Professor Andrew Davies presented the DLBCL Pathway and background to antibody-drug conjugates
- Dr Andrew McMillan presented the GO29365 randomised and extension cohort results
- Dr Lisa Lowry presented two patient case studies with POLIVY®▼ (polatuzumab vedotin) in combination with bendamustine (B) and rituximab (R) in the 2L R/R DLBCL setting
- Dr Wendy Osborne presented a patient case study with POLIVY + BR in the 4L R/R DLBCL setting
Date of preparation: May 2021